![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » KemPharm Receives Complete Response Letter for Acute Pain Candidate
KemPharm Receives Complete Response Letter for Acute Pain Candidate
June 20, 2016
The FDA has rejected KemPharm’s application for its abuse-deterrent, short-term acute pain management candidate Apadaz.
Company President and CEO Travis Mickle said the clinical-stage drugmaker is evaluating the points raised in the agency’s complete response letter and that it intends to request a meeting with the agency to determine the next steps.
Company spokesman Jim Heins declined further comment.
Upcoming Events
-
21Oct